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Abstract
Protein kinase C (PKC) is critical for T lymphocyte activation and proliferation, while nitric oxide synthase (NOS) may function both as
an activator or inhibitor of T cell apoptosis. Both enzymatic activities were studied in T lymphoma cells in comparison to normal and
activated T lymphocytes. Here we show a higher translocation of PKC in BW5147 lymphoma cells than in mitogen-stimulated T
lymphocytes. Tumor cells overexpressed PKC ~ isoform, while high levels of the PKC h isotype were found in mitogen-stimulated T
lymphocytes. Moreover, tumoral T cells showed high NOS activity, almost undetectable in normal or stimulated T lymphocytes. PKC and
NOS inhibitors or the intracellular delivery of an anti-PKC ~ antibody diminished both NO production and proliferation in tumor cells.
These results suggest that atypical PKC ~ isoform expression and its association with NOS activity regulation would participate in the
multistep process leading to BW5147 cell malignant transformation.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
The knowledge of the signaling events that control
cellular growth and differentiation is of paramount impor-
tance to understand the mechanisms involved in malignant
transformation. Particularly, in lymphoid cells, it has been
suggested that deregulation of intracellular pathways partic-
ipates in leukemic disorders [1]. Phosphorylation and
dephosphorylation of protein substrates by kinases and
phosphatases, respectively, play prominent roles in the
transduction of signals from cell membrane receptors to
the nucleus. Physiological activation of T lymphocytes
leading to differentiation and proliferation involves a com-
plex series of intracellular signaling events that is initiated
by protein tyrosine kinases (TPK) activation. The biochem-
ical cascade downstream includes increased hydrolysis of
inositol phospholipids, mediated by phospholipase C (PLC)
g1 phosphorylation, which gives rise to inositol triphos-
phate and diaciylglicerol (DAG). These second messengers,
in turn, increase intracellular Ca2 + concentrations and
activate protein kinase C (PKC), respectively [2,3].
PKC represents a family of serine/threonine kinases that
plays a central role in signal transduction as it is involved in
the control of numerous cellular processes, such as prolif-
eration and differentiation, as well as in carcinogenesis [4–
6]. Although all PKCs require the lipid phosphatidylserine
as a cofactor, differences in their structure and substrate
requirements allowed isoform classification into three sub-
classes: the conventional or classical PKCs (cPKC) (a, hI,
hII and g), which are Ca2 + -dependent and activated by
DAG and phorbol esters; the novel PKCs (nPKC) (y, q, D
and u), which can be activated by DAG and phorbol esters
but are Ca2 + -independent; and the atypical isoforms
(aPKC) (~ and H /E), which are unresponsive to both Ca2 +
and DAG or phorbol esters [5]. The existence of such a
large family of PKC isoenzymes, which exhibits different
tissue distribution, subcellular localization and biochemical
properties, suggests that individual PKC isoforms may play
specialized roles in cellular functions. In many cases, PKC
isoforms exhibit distinct and even opposing cellular effects
[7,8]. A differential expression of PKC isozymes has been
described for distinct hemopoietic lineages [9] and their
participation in determined cellular functions has also been
assigned. In fact, modulation of a and h isoform levels was
related to B lymphocyte differentiation [9] while particular
activation of atypical PKC ~ was demonstrated to participate
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in interleukin-2-mediated proliferation of T cells [10]. Also,
PKC u, an isoenzyme that was found predominantly in
hematopoietic cells and skeletal muscle, was demonstrated
to be expressed in T, but not in B lymphocytes, and played
an important role in T lymphocyte activation as an essential
component of the T-cell synapse [11,12].
On the other hand, nitric oxide (NO) is a physiologically
important signal molecule in many cells and tissues, regulat-
ing a variety of biological functions, including immune
processes [13]. The role of NO in the control of cell growth
is controversial since both stimulation and inhibition have
been demonstrated [14]. Also, NO exerts contrasting effects
on apoptosis, depending on its concentration, flux and cell
type, having, in some situations, an apoptotic effect while
protecting cells against spontaneous or induced apoptosis in
other [15]. The redox state of the cell seemed to be crucial for
the ultimate action of NO on cell multiplication and survival.
A protective antiapopatotic effect is commonly related to the
endogenous NO production through NO synthases (NOS)
and is frequently observed in lymphoid cells from B origin
[16,17]. Cells from a wide variety of malignancies have a
decreased ability to undergo apoptosis in response to some
physiological stimuli and inhibition of apoptosis can result in
the expression of cells with increased susceptibility to sub-
sequent malignant transformation [1,18]. Furthermore, pro-
duction of NO, as well as expression of different NOS
isoenzymes, both at the protein and mRNA level, were
demonstrated to be related to PKC activity in several cell
types including tumor cells [19,20]. Production of NO
downstream PKC was demonstrated to be induced by
immunopotentiators in splenic lymphocytes [21].
The present study was undertaken to analyze PKC
activity and isoenzyme expression and their relationship
with NO production in a T lymphoma cell line. Also their
contribution to cellular proliferation was analyzed. All these
studies were performed in comparison to normal unstimu-
lated and mitogen stimulated T cells. Here we report that
tumor T cells show significantly higher levels of PKC ~ and
increased NOS activity than resting or mitogen-stimulated
normal T lymphocytes. Intracellular delivery of PKC ~
isoform-specific antibodies results in a decrease of both
proliferation and NOS activity in tumor T cells. The
implications of these results in neoplastic transformation
are discussed.
2. Materials and methods
2.1. Cell suspensions and culture conditions
The tumor cell line BW5147 (a generous gift from Dr. A.
Schimpl, Institute fu¨r Virologie und Immunobiologie der
Universita¨t Wu¨rzburg, Germany) is a T cell lymphoma that
expresses H-2k haplotype, CD3 + and ah T cell receptor, as
tested routinely by flow cytometry with specific antibodies
against the corresponding surface markers. These cells were
cultured at an optimal concentration of 1–5 105 cells/ml,
in RPMI 1640 medium (GIBCO BRL) supplemented with
10% fetal calf serum (FCS), 2 mM glutamine and antibiotics,
with twice-weekly splitting once they have reached expo-
nential growth. Where indicated, synchronized (kept for 24 h
in FCS-deprived medium) BW5147 cells were used.
Aseptically prepared lymphoid cell suspensions from
C3H (H-2k) inbred mice lymph nodes were obtained from
nylon wool purification of T cells as described before
[22,23]. T cell purification was higher than 97% as checked
by lysis with anti-Thy plus complement and by indirect
immunofluorescence. Cells, at a concentration of 1106
cells/ml, were cultured in the same medium as tumor cells,
alone or in the presence of 2 Ag/ml of concanavalin A (Con
A), as previously described [22].
Cells were settled at a final volume of 0.2 ml in 96-well
flat-bottom microtiter plates (Nunck) for microcultures or
were kept in T-25 or T-75 culture flasks (Corning, NY) for
macrocultures. Cells were cultured for different times and
inhibitors were added at the beginning of the culture where
indicated.
2.2. Proliferation assays
Proliferation was evaluated on microcultures and con-
trolled in 0.2-ml aliquots of macrocultures established for
enzymatic assays.
The proliferation kinetics of BW5147 cells was deter-
mined on BW5147 synchronized cells after re-culturing
them in FCS-rich medium. Cells were pulsed with [3H]thy-
midine ([3H]TdR, NEN, 20 Ci/mmol) for the last 6 h of
incubation, as described before [22]. Results are expressed
as dpm values in experimental cultures subtracting the dpm
control values obtained on BW5147 synchronized cells. The
percentage of inhibition (% inh) for experimental cultures
performed in the presence of inhibitors was calculated as:
% inh
¼ 1 dpm BW5147 cellsþ inhibitor  dpm control
dpm BW5147 cells dpm control
 
 100
For Con A-stimulated T lymphocytes, cultures were
pulsed with [3H]TdR as indicated for BW5147 and cultures
of unstimulated cells were used as controls. The action of
inhibitors upon Con A-stimulated T cells was evaluated as
indicated for BW5147 cells.
It is worth noting that inhibitors alone do not signifi-
cantly modify either the basal control values of BW5147
(synchronized BW5147 cells) or the unstimulated cultures
of normal T lymphocytes.
2.3. PKC assay
Synchronized BW51457 cells (0.5 107 cells/sample)
were re-cultured for different times in FCS-rich medium
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alone or in the presence of the indicated drugs and were
immediately frozen in liquid N2. Normal or Con A-stimu-
lated T cells (1107 cells/sample) were incubated alone or
with inhibitors for the indicated times and processed as
tumor cells. PKC was purified from total cell extracts or
from subcellular fractions as previously described [24]. PKC
activity was assayed by measuring the incorporation of 32P
from [g-32P]-ATP into histone H1 [24]. Incubations were
conducted in a final volume of 85 Al at 30 jC for 30 min. In
the final concentrations, the assay mixture contained 25 AM
ATP (0.4 ACi), 10 mM Mg acetate, 5 mM h-mercaptoetha-
nol, 50 Ag of histone H1, 20 mM HEPES, pH = 7.5, 10 Ag/ml
of phosphatidylserine vesicles and in the presence or absence
of 0.2 mM CaCl2. The incorporation of [
32P]-phosphate into
histone was linear for at least 30 min. The reaction was
stopped by the addition of 2 ml of ice-cold 5% trichloroacetic
acid with 10 mM H3PO4. The radioactivity retained on GF/C
glass fiber filters after filtration was determined by counting
the filters in 2 ml of scintillation fluid. PKC activity was
determined after subtracting the 32P-incorporation in the
absence of Ca2 + and phospholipids. Data were expressed
as picomoles of phosphate incorporated into the substrate per
minute and per 107 cells (pmol/min/107 cells). The selective
PKC substrate peptide, MBP(4–14) [25] (GIBCO BRL),
was also used to measure PKC activity purified from sub-
cellular lymphoid fractions, following the instructions of the
PKC assay system from GIBCO BRL. PKC specificity was
confirmed by the PKC pseudosubstrate inhibitor peptide
PKC (19–36) provided by GIBCO BRL.
2.4. NOS activity determination
NOS activity was measured by production of [U-14C]-
citrulline from [U-14C]-arginine [26]. Briefly, cells were
incubated in 500-Al RPMI-1640, in the presence of [U-14C]-
arginine (0.5 ACi). After incubation, cells were disrupted by
sonication (Vibra-cell, Sonics and Materials) in a medium
containing 10 mmol/l EGTA, 0.1 mmol/l citrulline, 0.1
mmol/l dithiothreitol and 20 mmol/l HEPES, pH 7.5. After
centrifugation at 20,000 g for 10 min, supernatants were
applied to 2-ml columns of Dowex AG 50WX-8 (sodium
form, Bio-Rad) and [U-14C]-citrulline was eluted with 3 ml
of water and quantified by liquid scintillation counter.
2.5. Immunoblot analysis of PKC isoenzymes
Samples of whole cell lysates from tumor and normal T
lymphocytes were prepared by dissolving cellular pellets in
SDS-sample buffer (2% SDS, 10% (v/v) glycerol, 62.5 mM
Tris–HCl, pH = 6.8, 0.2% bromophenol blue, 1% (v/v) 2-
mercaptoethanol) at a final concentration of 10 mg/ml.
Equal amounts of proteins were separated by SDS-PAGE
on 10% polyacrylamide gels and transferred to nitrocellu-
lose membranes. Where indicated, cytosol and particulate
fractions of unstimulated or stimulated cells, obtained as
described by Meller et al. [27], representing 2 106 cell
equivalents per 10 Al and supplemented with 2.5-Al 5
SDS sample buffer, were analyzed by SDS-PAGE and
immunoblotted, as above.
Nonspecific binding sites in nitrocellulose membranes
were blocked with blocking buffer (5% nonfat dried milk,
containing 0.1% Tween-20 in 100 mM Tris–HCl, pH = 7.5
and 0.9% NaCl) for 1 h. The nitrocellulose was subse-
quently incubated with protein G-purified anti-peptide anti-
bodies to specific PKC isoforms for 18 h. Anti-PKC
isoenzyme specific antibodies from GIBCO BRL are poly-
clonal antibodies raised against specific peptides from each
isoenzyme. The a-, h- and g-specific antibodies were raised
against the peptides corresponding to amino acids 313–326,
313–329 and 306–318, respectively, derived from murine
cDNA sequences. The y-, q- and ~-specific antibodies were
raised against C-terminal peptides corresponding to amino
acids 662–673, 726–737 and 577–592, respectively. The
anti-PKC u antibody (C-18, from Santa Cruz Biotechnolo-
gies) specific for an epitope mapping at the carboxy
terminus of nPKC u of mouse origin was also used.
Negative controls were incubated in the presence of immu-
nogenic peptides at a concentration 2 Ag/ml antibody to 1
Ag/ml peptide. The membrane was then incubated with a
monoclonal anti-rabbit IgG alkaline phosphatase conjugate
(Sigma Chemical Co.) for 1 h. Immunoreactive bands were
visualized using nitroblue tetrazolium (NBT) and 5-bromo-
4-chloro-3-indolyl-phosphate (BCIP). As molecular weight
markers, a Full Range Rainbow (Amersham Pharmacia) was
used. Anti-actin antibody (rabbit polyclonal, against actin of
human origin, but cross-reactive to mouse actin, from Santa
Cruz Biotechnol.) was used as a control for protein loaded.
Densitometric analysis was performed by UN-SCAN-IT
(version 5.1, Silk Scientific Corporation) software. Densito-
metric values of actin (arbitrary units) for each gel were
normalized relative to each other and PKC densitometry
values (arbitrary units) in each lane were divided by the
corresponding normalized actin value.
2.6. Intracellular delivery of anti-PKC ~ antibody in normal
and tumor T cells
Anti-PKC ~ antibody against the C-terminal region of
PKC (GIBCO BRL) was introduced into normal or
BW5147 tumor T cells after permeabilization with lysole-
cithin as described [28]. Briefly, BW5147 cells were equi-
librated in 7% FCS-containing medium for 24 h. Normal
cells or tumor cells, cultured as indicated, were washed with
serum-free medium and 0.1-ml glycerol in PBS at 37 jC
was added. After 6 min on ice, 4 Al of a 1 mg/ml
lysolecithin (Sigma) solution in water was added, and the
incubation continued for an additional 5 min. Cells were
then brought to 37 jC and 0.1 ml of a dilution of antibody
(alone or preincubated with 3 concentration of the cor-
responding peptide) was added. After 10 additional minutes
at 37 jC, during which the cells reseal, 0.1 ml of medium
containing 21% FCS was added. Cells were brought back to
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the 7% FCS-containing medium. Incubations were contin-
ued for 72 h, in the presence of 2 Ag/ml Con A, for normal T
cells or 24 h for BW5147 cells. Control untreated cells were
submitted to the same permeabilization schedule than intra-
cellular antibody-delivered cells. Proliferation was eval-
uated by [3H]TdR incorporation by adding the radioligand
substrate 6 h prior to culture finalization. NOS enzymatic
activity was evaluated immediately upon the ending time of
incubation, as indicated before.
2.7. Drugs
The following drugs were used in cultures at the final
concentrations indicated in Results. The protein kinase
inhibitors staurosporine, the selective PKC inhibitor GF-
109203X (bisindolylmaleimide), the PLC blocker 2-nitro-4-
carboxyphenyl-N,N-diphenylcarbamate (NCDC) and the
TPK inhibitor genistein (all from Sigma) were dissolved
in DMSO. NG-Nitro-L-arginine methyl ester (L-NAME)
(RBI, USA) was dissolved in water. Stock solutions were
freshly prepared before use. All drugs were further diluted
(at least 1:1000 or more) in RPMI 1640 medium to achieve
the concentrations indicated in Results.
2.8. Statistical analysis
The Student’s t-test for unpaired values was used to
determine the levels of significance. When multiple com-
parison were necessary after analysis of variance, the
Student–Newman–Keuls test was applied. Differences
between means were considered significant if PV 0.05.
3. Results
3.1. Blockers of intracellular pathways involved in T
lymphocyte activation displayed different actions on mito-
gen-stimulated and tumor T cell proliferation
In order to analyze differences in the enzymatic intra-
cellular pathways involved in both mitogen-induced and
tumor T cell proliferation, the effect of TPK, PLC, PKC and
calcium blockers was analyzed. As shown in Fig. 1, the
blockade of TPK by genistein, at a dose that has no effect on
cellular viability, PLC by NCDC or PKC by either staur-
osporine or the more selective GF109203X inhibit both
normal and tumor cell proliferation. It is worth noting that
Fig. 1. Effect of different enzymatic and calcium blockers on Con A-
stimulated and tumor T cell proliferation. Purified T lymphocytes were
prepared aseptically following the indicated procedures and stimulated with
Con A (2 Ag/ml), for 72 h (T). Cells were cultured in the absence (basal) or
presence of the drugs mentioned above. BW5147 synchronized cells ( )
were incubated for 24 h in FCS-rich medium alone (basal) or with the
indicated blockers. The following blockers, added at the beginning of
culture, were used: genistein (GEN) (30 Ag/ml), NCDC (10 AM),
staurosporine (STAU) (0.1 AM), GF109203X (GF) (0.1 or 10 AM),
verapamil (VER) (0.1 mM) and L-NAME (L-NA) (5 mM). Proliferation
was evaluated by [3H]TdR incorporation. Percentage of inhibition of
cellular proliferative activity, calculated as described in Materials and
methods, is shown between brackets. Results shown are the meanF SD of
three independent experiments performed in triplicate. *Differs signifi-
cantly from the corresponding basal value with at least P < 0.01. #Differs
significantly from the other values of BW5147 cells with at least P < 0.05.
Fig. 2. Calcium dependence of PKC total activity in normal and tumor T
cells. PKC total activity was purified from normal T lymphocytes (TN,
white bars) or tumor BW5147 cells (gray bars) and was measured, in the
presence (open bars) or in the absence of Ca2 + (dashed bars), using the
substrate MBP (4–14), as described in Materials and methods. Results
shown are the meanF SD from four independent experiments performed in
duplicate. *Differs significantly from the corresponding basal value with
P < 0.01.
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GF109203X is a potent inhibitor of cPKC (IC50i0.01–
0.02 AM), but a weak inhibitor of nPKC (IC50i0.1–0.2
AM) or aPKC (IC50 for PKC ~i6.0 AM) [7]. So, the fact
that this blocker exerted a significant higher effect at 10 AM
than 0.1 AM concentration could be related to the different
IC50 s. Furthermore, the calcium blocker verapamil,
although efficiently inhibiting Con A-stimulated prolifera-
tion, had little effect on T lymphoma cell growth.
To assess the role of cell-specific pathways for NO in
normal and tumor cells, the action of the NOS competitive
blocker, L-NAME, was also determined. Fig. 1 also shows
that L-NAME was able to abrogate tumor, but not normal, T
cell proliferation.
3.2. PKC and NOS activities in normal, activated and tumor
T cells
To compare PKC activity on both normal and tumor cells
and to evaluate the balance between calcium-dependent and
independent PKC isoforms, enzymatic activity was meas-
ured on whole cell extracts in the presence or absence of
Ca2 + using the specific PKC substrate, MBP (4–14) pep-
tide. As shown in Fig. 2, total PKC activity was higher in
tumor than in normal T cells, and it was unaffected in the
absence of Ca2 + . In normal T cells a decrease of approx-
imately 43% was observed in the absence of Ca2 + .
To analyze differences in PKC translocation to plasma
membrane, related to cellular proliferation in both normal
and tumor T lymphocytes, PKC enzymatic activity was
measured on both soluble and particulate fractions from
mitogen-stimulated normal and tumor T cell, at different
times during the kinetics of proliferation. For this purpose
BW5147 synchronized cells were induced to proliferate by
re-culturing them in FCS-rich medium. Resting normal T
lymphocytes were activated by Con A in vitro as indicated
before. As shown in Fig. 3 and in accordance to Fig. 2, total
PKC activity was higher on synchronized tumor (basal) than
in normal T cells. Within 15-min exposure to FCS,
synchronized BW5147 cells displayed an early and signifi-
cant increment in membrane PKC activity that was accom-
panied by the decrease in cytosolic PKC (Table in Fig. 3).
The increment in phosphorylated substrate was observed
Fig. 3. PKC activity and proliferation of normal, mitogen-stimulated and tumor T cells. Panel A: Normal T lymphocytes were kept in culture alone (basal) or in
the presence of Con A (2 Ag/ml) for the indicated times. Proliferation (curve) was evaluated by [3H]TdR incorporation, in 0.2-ml aliquots of macrocultures
established for enzymatic PKC activity determination. Results shown are the meanF SD of three independent experiments performed in triplicate. PKC
activity in membrane fractions was determined using MBP (4–14) as described in Materials and methods and percent of total (cytosol +membrane) PKC
activity (bars) from the three experiments performed in duplicate were calculated. Panel B: BW5147 cells, synchronized by 24-h culture in FCS-deprived
medium, were recultured in FCS-rich RPMI 1640 medium as indicated before. Proliferation (curve) was evaluated by 6 h lasting pulses of [3H]TdR, as
indicated in panel A, on BW5147 synchronized (without FCS, basal) and after resetting them in FCS-rich medium for the indicated times. Results shown are
the meanF SD of three experiments performed in triplicate. Percentages of total PKC activity corresponding to membrane purified fractions determined as in
Panel A are shown in the bar graphic.
A summary of both PKC activity (pmol/107 cells) and proliferation (dpm) is shown in the adjoining table. (a) PKC activity values from purified cytosol and
membrane fractions corresponding to basal or 15 min treatment with Con A (normal T cells) or with FCS-rich medium (BW5147 cells) are shown. Results are
the meanF SD of three experiments performed in duplicate. (b) Mean dpmF SD of [3H]TdR incorporation corresponding to basal or to the peak of
proliferation (72 h for Con A-treated T lymphocytes or 14 h for BW5147 cells). * Differs from basal values with at least P< 0.01. * #Differs from basal values
and from Con A-stimulated T cells with at least P< 0.01.
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both when using histone H1 (data not shown) or the specific
PKC peptide MBP (4–14). This membrane PKC activity
diminished but stayed higher than basal values after the
peak of proliferation. It is worth noting that exponentially
growing BW5147 cells displayed similar values for total
PKC activity, with most of this activity (80–90%) in
membrane fractions.
On the other hand, mitogenic stimulation of resting
normal T lymphocytes also induced an early translocation
of PKC (within 15 min), but to a lesser extent to that found
in tumor cells. Membrane PKC returns to basal levels after
the peak of proliferation.
With respect to NOS activity, we found very low levels
in normal T cells (Fig. 4), with a slight nonsignificant
increase upon physiologic activation. On the contrary,
BW5147 cells showed an important basal NOS activity,
which was blunted by L-NAME (Fig. 4); an effect that was
reverted by L-arginine (data not shown). To analyze the
relationship between high PKC and NOS activities in
BW5147 cells, the effect of PKC blockers on NOS was
also determined. As can be seen in Fig. 4, both staurospor-
ine and GF109203X in high doses were able to inhibit,
similarly, NOS activity in tumor cells.
3.3. PKC isoform expression in mitogen-activated and
tumor T cells
In order to asses that differences in PKC activity could
be related to distinct isoenzyme expression, PKC isoform
profile was analyzed on both tumor and resting or mitogen-
stimulated T cells by Western blot analysis. The expression
of cPKC a and h, nPKC y, u and q, and the atypical PKC
~ isoform in lysates from naive or Con A-stimulated T cells
and exponentially growing BW5147 cells was measured. A
representative plot of the levels of PKC isoenzymes in the
different cell types is shown in Fig. 5 (Panel A). As can be
seen, resting T cells express the cPKC a and h and the
nPKC u, but not g (data not shown) isoform with barely
detectable amounts of PKC y and ~ . As an example of
PKC translocation upon cellular activation, within 15 min
of mitogenic stimulation, membrane levels of cPKC h
isoform were increased in membrane fractions (Fig. 5,
Panel B). Also, after 72 h of Con A treatment, a significant
increase in levels of cPKC a and h was observed. On the
contrary, exponentially growing BW5147 cells showed
only vanishing amounts of the h isoform and an increased
expression of PKC ~ (Fig. 5, Panel A). Whereas levels of
a, g, y and q isoforms were identical to those found in
activated normal T lymphocytes of the same H-2 haplotype
(Fig. 5A), expression of the u isotype was not found. It is
worth noting that all the bands were detected at the
positions corresponding to PKC isoenzymes from T lym-
phoid cells previously described [29]. PKC ~ translocation
to the particulate fraction was obtained upon 15-min
stimulation of synchronized BW5147 cells with FCS
(Fig. 5, Panel B).
3.4. Effect of the intracellular delivery of anti-PKC ~
isoform antibody on BW5147 proliferation and NOS activity
In order to determine the involvement of PKC ~ in the
high proliferative rate and NOS activity from tumor T cells,
the effect of intracellular delivering of a specific antibody
against the C-terminal region of PKC ~ , was assessed. Anti-
PKC ~ antibody (Fig. 6) was able to diminish, in the
concentrations tested, both proliferation and NOS activity
in BW5147 cells, but not in normal activated T lympho-
cytes. It is worth noting that no differences from basal
values with dilutions higher than 1:500 (data not shown)
Fig. 4. NOS activity in normal, mitogen-stimulated and tumor T cells. Panel
A: NOS activity was measured by the conversion of [14C]-arginine to [14C]-
citrulline as indicated in Materials and methods in normal T lymphocytes
(T), basal or Con A-stimulated for 48 or 72 h, or BW5147 ( ) cells.
Panel B: Effect of the PKC blockers, staurosporine (Stau, 0.1 AM) or
GF109203X (GF, 10 AM) and the NOS blocker, L-NAME (5mM), on
BW5147 cells incubated alone (Basal) or in the presence of the indicated
blocker concentrations for 24 h is shown. Results are the meanF SD of
n= 4 experiments. *Differs significantly from basal values with at least
P < 0.05.
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Fig. 5. PKC isotype expression in normal (TN), Con A-stimulated (TN-Con A) or BW5147 T cells. Panel A: The data show the Western blot analysis of PKC
a, h, u, y, q and ~ isotypes. Specificity of anti-PKC antibodies was assessed by performing Western blot analyses in the absence ( ) or presence (+) of the
corresponding peptide against which the antibodies had been raised. Results, corresponding to TN, TN-Con A (culturing time 72 h) and BW5147 total cells, are
representative of seven independent experiments. Anti-actin antibodies were tested on same samples used for PKC isoform analysis as control for protein
loading in three of these experiments. Also, PKC levels for each isoenzyme (bar graph) were calculated in relation to the expression level of actin in the same
sample as described in Materials and methods. Results shown are the meanF SD of n= 3 experiments. Statistic analysis was performed within each isoenzyme
group. *Differs significantly from TN and BW values with at least P < 0.01. #Differs significantly from TN and TN-Con Avalues with at least P < 0.001. Panel
B: Subcellular distribution of PKC h and ~ isoenzymes in normal and tumor T cells, respectively, upon cellular activation. Freshly isolated T lymphocytes or
synchronyzed BW5147 cells were either left unstimulated ( ) or stimulated (+) with Con A (2 Ag/ml) or FCS (10%), respectively, for 15 min. Cytosol and
membrane fraction of 2 106 cell equivalents were analyzed by SDS-PAGE followed by immunoblotting with the indicated antibodies. Arrows indicate the
position of the corresponding PKC protein bands. The relative intensity of the different PKC bands was quantitated by densitometry and the percentage of the
membranal PKC out of the sum of cytosolic plus membranal PKC was calculated in each case and represented in the bar graph. It is worth noting that both
Western blots and the bar graph are one representative out of three experiments.
G. Gorelik et al. / Biochimica et Biophysica Acta 1588 (2002) 179–188 185
were found in tumor cells. These effects were blunted by
pretreatment of the antibody with the specific immunogenic
~ peptide (Fig. 6).
4. Discussion
Both PKC and NOS activities play important roles in the
regulation of cellular functions. In this work the involve-
ment of these enzymatic pathways in the proliferation of a T
lymphoma cell line was studied in comparison to normal
and mitogen-stimulated T lymphocytes. Tumor BW5147
cells exhibit higher total PKC activity and membrane PKC
translocation than normal or mitogen-stimulated T cells. In
normal T lymphocytes, PKC activity was diminished in the
absence of calcium, while it was almost unmodified in
tumor cells, thus pointing to a prevalence of calcium-
independent PKC isoform activity in tumor cells in compar-
ison to normal lymphocytes. It is worth noting that the
calcium blocker verapamil inhibits Con A-induced prolifer-
ation of normal cells, but has not a significative effect in the
proliferation of BW5147 cells. PKC inhibitors or blockers
of the upstream signaling pathways, namely, TPK and PLC,
are capable of inhibiting both mitogen-stimulated and tumor
T cell proliferation. GF109203X, a potent inhibitor of cPKC
but a weak inhibitor of calcium-independent isoforms, was
able to efficiently block tumor cell proliferation at high
doses, while equally inhibiting Con A-stimulated prolifer-
ation at low and high doses. These results indicate that
different PKC isoforms would have differential hierarchical
participation in normal and tumor T cell activation. The
higher PKC translocation observed in tumor cells with
respect to the physiologic translocation induced by the
mitogenic stimulus would point to the participation of this
intracellular transduction mechanism in the sustained pro-
liferation of BW5147 cells. In fact, a correlation has been
proposed between PKC activity and the rate of cellular
growth, as well as a parallelism between PKC inhibition and
induction of cellular differentiation in lymphoid cells [4].
Several experimental evidences indicate that PKC iso-
enzymes are localized in specific tissues and that different
isoforms are related to lymphoid proliferation or differ-
entiation [4,9,10], so the pattern of PKC isoenzymes was
studied on both normal and tumor T cells. We found that
normal and activated T lymphocytes display the calcium-
dependent a and h PKC isoforms, as well as the nPKC u,
and detectable levels of q and ~ , with no expression of the g
isoenzyme. Similarly, Mischak et al. [9] found the expres-
sion of mRNA encoding for a and h, but not g isoforms,
with low levels of PKC q and ~ , in resting murine T
lymphocytes and a close correlation between protein expres-
sion and mRNA levels. With respect to the u isoform, its
expression and role in T cell activation was already dem-
onstrated [27]. The expression of cPKC a and h was
progressively up-regulated by Con A stimulation and this
correlates with cell proliferation. Several stimuli, including
mitogens, were demonstrated to induce changes in T lym-
phocyte PKC isoenzyme expression, both at protein and
mRNA levels [30–32]. These changes were time- and cell-
type-dependent. Thus, a decrease in PKC h protein levels
within 24 h of mitogen stimulation [30] and an earlier but
transient loss of h and a PKC mRNA were described in
murine thymocytes [31]. Despite this, Isakov et al. [32]
demonstrate that mitogen stimulation of human mature T
cells is followed by a four- to fivefold increase in PKC a
and h mRNA, peaking at 48 h and correlating with cellular
proliferation, which is in agreement with our results. Differ-
ences from the data of Strulovici [30] could be related with
the distinct T cell populations studied.
BW5147 cells have barely detectable levels of the h
isoform, with similar levels of a and y isoforms, and no
detectable levels of the g and u isoenzymes. Interestingly,
we found an increased expression of the atypical calcium-
Fig. 6. Effect of intracellular delivery of an anti-PKC ~ antibody on cellular
proliferation and NOS activity. Panel A: BW5147 cells were permeabilized
with lysolecithin and incubated in the absence or presence of different
dilutions of the anti-PKC ~ for 10 min and resealed. After 24 h of
incubation, cellular proliferation was assessed as described before. Panel B:
both normal or tumor cells were permeabilized, as indicated in panel A, and
incubated in the absence or presence of anti-PKC ~ antibody (in a
concentration 1:200) or anti-PKC ~ plus PKC ~ peptide (1:3). After
resealing, BW5147 cells were incubated for 24 h and normal cells were
stimulated with Con A (TN-Con A) for 72 h. Proliferation and NOS activity
were measured as described. Results shown are the meanF SD of three
independent experiments. *Differs significantly from the corresponding
basal (none) values with at least P< 0.05.
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independent ~ isoenzyme. These results are in agreement
with the fact that cellular proliferation is mainly calcium-
independent in BW5147 cells, and PKC activity involves
calcium-independent isoforms, as it was not modified in the
presence of EGTA. Goodnight et al. [33] have described
elevated expression of PKC ~ in B lymphocytic neoplasms
at both mRNA and protein levels. Also, a high expression of
the h isoform has been related to accelerated leukemic cell
differentiation [34], while final differentiation of B lympho-
cytes into antibody-secreting plasma cells is accompanied
by a loss in this isoenzyme [9]. Taken together, these facts
and our results, it is possible that the increase in PKC h
isoform observed during mitogenic stimulation of T cells
would allow an efficient but limited activation, leading to
differentiation to immune effector cells, while low levels of
this isoenzyme, together with high levels of the ~ isoform,
would be responsible for the hyperproliferative pattern of
BW5147 cell line.
On the other hand, the NOS blocker L-NAME impaired
tumor, but not normal T cell proliferation. Also, BW5147
cells exhibit high NOS activity, while a low basal activity
was found in resting normal T cells, which was not
increased by mitogenic stimulation. High NOS activity
levels in tumor cells were blunted by L-NAME and were
partially impaired by PKC blockers, thus indicating that
PKC activity is, in part, responsible for NOS activity in
BW5147 cells. High levels of endogenous NOS activity
would allow the survival of tumor cells, protecting them
from apoptotic mechanisms. Furthermore, intracellular
delivery of an antibody directed to the most abundant
PKC isoform in BW5147 cells, an anti-PKC ~ antibody,
not only diminished cellular proliferation, but also lowered
NOS activity in tumor cells, with no effect on mitogen-
activated T lymphocytes. Other authors have previously
demonstrated that intracellular delivery of antibodies direc-
ted to the C-terminal region of specific PKC isoforms are
able to modify physiological functions of different cell types
[28], including T lymphocytes [35]. In support to our
results, overexpression of PKC ~ isoform was demonstrated
to markedly increase the inducible NOS isoenzyme expres-
sion in rat mesangial cells [36]. The fact that anti-PKC ~
antibody was not able to completely abrogate NOS activity
or proliferation of BW5147 cells indicates that probably
other isoforms could be involved in these functions, but
nevertheless, they point to a role for the PKC ~ isoenzyme.
Actually, PKC activation by phorbol esters, which activates
cPKC and nPKC but not aPKC, was demonstrated to
increase NOS expression and/or activity in several cell
types [19,20,26,37].
Experimental evidence showed that aPKCs play impor-
tant roles in controlling cell growth and survival [38]. In
fact, it was demonstrated that PKC ~ is critical for mitogenic
signal transduction in oocytes [39], while aPKC H was
shown to protect human leukemic cells from drug-induced
apoptosis [40]. Furthermore, Tsutsumi et al. [41] demon-
strated the down-regulation of PKC ~ RNA following cross-
linking of membrane IgM on B lymphoma cells, and growth
arrest and apoptosis were induced in a B cell line by cross-
linking of surface immunoglobulin [42]. There are also
evidences that endothelial NOS autocrine is able to protect
T lymphocytes from apoptosis [43].
For the first time, shown here are evidences that strength-
ened the crosstalk of PKC and NOS enzymatic pathways in
T lymphoid cells and their participation in cellular prolifer-
ation. Although further studies would be necessary to
analyze the role of other isoforms, our results would indicate
that hyperproliferation of BW5147 cells is related to PKC
hyperactivity, with a major participation of calcium-inde-
pendent isoenzymes and particularly of PKC ~ . This activity
is in part responsible for inducing NOS activation that
would protect BW5147 cells from apoptotic signals, con-
tributing in this way to cellular survival. Our findings also
suggest that the PKC ~ member of the PKC multigene
family participates in the multistep process of BW5147 cell
growth, leading to the malignant phenotype.
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